Lonza's Strategic Divestment

Lonza’s shares rose over 6% on Thursday after announcing plans to divest its Capsules & Health Ingredients (CHI) unit to sharpen focus on drug development and manufacturing.

The divestment aligns with Lonza's "One Lonza" strategy, aiming to streamline operations and enhance shareholder value. By exiting the CHI business, the company intends to concentrate resources on higher therapeutic and commercial value areas, such as its CDMO offerings.

The CHI unit, facing market challenges, will have a gradual exit by 2025. This decision is expected to benefit shareholders, customers, and employees, with detailed next steps to be announced later.

While CHI's sales outlook for 2025 remains modest, the CDMO segment is projected to achieve significant growth, targeting a 20% sales increase at constant exchange rates.

Lonza’s CDMO operations will be consolidated into three integrated platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, intended to improve scalability, execution, and customer service. The full operational shift is expected by Q2 2025.

Lonza reaffirmed its dividend policy, signaling confidence in its strategic direction and commitment to increase payouts year-on-year.

Analysts at RBC suggested that a mid-term organic growth guide in low teens, along with mid-to-high teens capex, makes sense, despite the withdrawal of a specific margin target. Lonza's focus on its CDMO core reflects a commitment to leveraging industry reputation, long-term customer relationships, and technological expertise for sustainable growth.